K Number
K241516
Device Name
BTL-398
Date Cleared
2025-02-10

(257 days)

Product Code
Regulation Number
876.5320
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The device is intended to provide entirely non-invasive electromagnetic stimulation of pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
Device Description
The BTL-398 is a non-invasive therapeutic device that delivers magnetic pulses to stimulate the pelvic floor muscles for the treatment of urinary incontinence in adult population. The BTL-398 device is intended for professional use in healthcare facilities as a prescription use only. The BTL-398 consists of a main unit and a Chair Applicator. The main unit consists of the electromagnetic field generators, the microprocessor-driven control unit, and the touch-screen control panel. The Chair Applicator is designed for non-invasive treatment of urinary incontinence. The magnetic coil is in the center of the seat, and its position is user-adjustable during therapy. Ongoing therapy is indicated by illuminated segments. The Chair Applicator is designed for precise patient positioning, ensuring the most appropriate posture before and during therapy. Prior to High-Intensity Focused Electromagnetic (HIFEM) therapy, the seat height and coil position can be adjusted using an attached remote controller. The Dynamic HFEM Technology (DHT) feature ensures the coil is optimally positioned at the right location beneath the patient before starting therapy. At the start of therapy, air is circulated through the seat cushion with the Pressure Wave Technology (PWT) feature (intensity of the PWT function is set based on patient feedback). The PWT feature helps patients maintain the correct therapeutic position during therapy. Both the PWT and DHT features can be readjusted, and the PWT feature can be turned off, at any time during the session. The touch screen display guides the user step-by-step through the entire therapy procedure. During therapy, the screen displays information about the applied therapy, remaining therapy time, and main therapy parameters. Therapy is administered through clothing.
More Information

Not Found

No
The description focuses on hardware components, electromagnetic stimulation, and basic control features. There is no mention of AI/ML terms, data analysis for learning, or adaptive algorithms based on patient data beyond simple feedback adjustments.

Yes
The device description explicitly states, "The BTL-398 is a non-invasive therapeutic device..." and its intended use is for "rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence."

No
The device description states it is a "non-invasive therapeutic device that delivers magnetic pulses to stimulate the pelvic floor muscles for the treatment of urinary incontinence." Its purpose is rehabilitation and restoration of control, not diagnosis.

No

The device description explicitly details hardware components such as a main unit with electromagnetic field generators, a Chair Applicator with a magnetic coil, a touch-screen control panel, and a remote controller. It also mentions features like Pressure Wave Technology (PWT) and Dynamic HFEM Technology (DHT) which involve physical mechanisms. While software is mentioned for control and guidance, the device is clearly a combination of hardware and software.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is to provide non-invasive electromagnetic stimulation for the rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of urinary incontinence. This is a therapeutic purpose, not a diagnostic one.
  • Device Description: The device delivers magnetic pulses to stimulate muscles. It does not analyze samples from the human body (like blood, urine, or tissue) to provide diagnostic information.
  • Lack of IVD Characteristics: The description does not mention any components or functions related to in vitro testing, such as reagents, sample handling, or analysis of biological specimens.

In summary, the device is a therapeutic device that uses physical means (electromagnetic stimulation) to treat a medical condition, rather than an IVD which is used to diagnose a condition by examining samples outside the body.

N/A

Intended Use / Indications for Use

The device is intended to provide entirely non-invasive electromagnetic stimulation of pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.

Product codes

KPI

Device Description

The BTL-398 is a non-invasive therapeutic device that delivers magnetic pulses to stimulate the pelvic floor muscles for the treatment of urinary incontinence in adult population. The BTL-398 device is intended for professional use in healthcare facilities as a prescription use only.

The BTL-398 consists of a main unit and a Chair Applicator. The main unit consists of the electromagnetic field generators, the microprocessor-driven control unit, and the touch-screen control panel. The Chair Applicator is designed for non-invasive treatment of urinary incontinence. The magnetic coil is in the center of the seat, and its position is user-adjustable during therapy. Ongoing therapy is indicated by illuminated segments.

The Chair Applicator is designed for precise patient positioning, ensuring the most appropriate posture before and during therapy. Prior to High-Intensity Focused Electromagnetic (HIFEM) therapy, the seat height and coil position can be adjusted using an attached remote controller. The Dynamic HFEM Technology (DHT) feature ensures the coil is optimally positioned at the right location beneath the patient before starting therapy. At the start of therapy, air is circulated through the seat cushion with the Pressure Wave Technology (PWT) feature (intensity of the PWT function is set based on patient feedback). The PWT feature helps patients maintain the correct therapeutic position during therapy. Both the PWT and DHT features can be readjusted, and the PWT feature can be turned off, at any time during the session. The touch screen display guides the user step-by-step through the entire therapy procedure. During therapy, the screen displays information about the applied therapy, remaining therapy time, and main therapy parameters. Therapy is administered through clothing.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

pelvic floor

Indicated Patient Age Range

Adult

Intended User / Care Setting

professional use in healthcare facilities

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

  • Electrical Safety testing, mechanical strength testing and thermal safety testing to IEC 60601-1: 2020 - Medical electrical equipment -Basic safety and essential performance.
  • Electromagnetic Compatibility testing according to IEC 60601-1-2: 2020 General requirements for basic safety and essential performance -- Collateral Standard: Electromagnetic disturbances -- Requirements and tests.
  • Software Verification and Validation Testing according to FDA's Guidance (2023) "Content of Premarket Submissions for Device Software Functions | FDA"
  • Additionally, performance bench data was submitted for device performance i.e., magnetic field strength testing, coil surface temperature testing/controls and PWT feature testing.
    All pre-determined acceptance criteria were met.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K181497

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 876.5320 Nonimplanted electrical continence device.

(a)
Identification. A nonimplanted electrical continence device is a device that consists of a pair of electrodes on a plug or a pessary that are connected by an electrical cable to a battery-powered pulse source. The plug or pessary is inserted into the rectum or into the vagina and used to stimulate the muscles of the pelvic floor to maintain urinary or fecal continence. When necessary, the plug or pessary may be removed by the user. This device excludes an AC-powered nonimplanted electrical continence device and the powered vaginal muscle stimulator for therapeutic use (§ 884.5940).(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The FDA part of the logo is in blue, with the acronym in a square and the full name written out as "U.S. Food & Drug Administration".

February 10, 2025

BTL Industries, Inc. David Chmel CEO North America 362 Elm Street Marlborough, Massachusetts 01752

Re: K241516 Trade/Device Name: Btl-398 Regulation Number: 21 CFR 876.5320 Regulation Name: Nonimplanted Electrical Continence Device Regulatory Class: II Product Code: KPI Dated: May 28, 2024 Received: January 8, 2025

Dear David Chmel:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

1

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rue"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See

2

the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jessica K. Nguyen -S

Jessica K. Nguyen, Ph.D. Assistant Director DHT3B: Division of Reproductive, Gynecology, and Urology Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

3

Indications for Use

510(k) Number (if known) K241516

Device Name Btl-398

Indications for Use (Describe)

The device is intended to provide entirely non-invasive electromagnetic stimulation of pelvic flor the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.

Type of Use (Select one or both, as applicable)
-------------------------------------------------

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

4

Image /page/4/Picture/0 description: The image contains the logo for BTL Industries. The logo consists of three interconnected squares with the letters "BTL" inside. To the right of the logo is the text "BTL Industries" in a sans-serif font.

Traditional 510(k) Summary

1. Submitter Information

| Applicant | BTL Industries, Inc.
362 Elm Street
Marlborough, MA 01752
Tel: +1-866-285-1656
Fax: +1-888-499-2502 |
|------------------------|-----------------------------------------------------------------------------------------------------------------|
| Official Correspondent | David Chmel
BTL Industries, Inc.
chmel@btlnet.com |
| Date Prepared: | February 7, 2025 |

2. Device Name

Trade/Proprietary Name:BTL-398
Common Name:BTL-398
Primary Classification Name:Nonimplanted electrical continence device
Classification Regulation:21 CFR 876.5320, Class II
Classification Product Code:KPI

5

Image /page/5/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of a geometric design on the left, followed by the text "BTL Industries" on the right. The geometric design is made up of three nested squares, with the letters "B", "T", and "L" inside the innermost square. The text "BTL Industries" is in a sans-serif font and is a dark gray color.

3. Predicate Device Identification

K181497 HPM-6000UF BTL Industries, Inc.

The predicate device was never subjected to a design related recall.

4. Device Description

The BTL-398 is a non-invasive therapeutic device that delivers magnetic pulses to stimulate the pelvic floor muscles for the treatment of urinary incontinence in adult population. The BTL-398 device is intended for professional use in healthcare facilities as a prescription use only.

The BTL-398 consists of a main unit and a Chair Applicator. The main unit consists of the electromagnetic field generators, the microprocessor-driven control unit, and the touch-screen control panel. The Chair Applicator is designed for non-invasive treatment of urinary incontinence. The magnetic coil is in the center of the seat, and its position is user-adjustable during therapy. Ongoing therapy is indicated by illuminated segments.

The Chair Applicator is designed for precise patient positioning, ensuring the most appropriate posture before and during therapy. Prior to High-Intensity Focused Electromagnetic (HIFEM) therapy, the seat height and coil position can be adjusted using an attached remote controller. The Dynamic HFEM Technology (DHT) feature ensures the coil is optimally positioned at the right location beneath the patient before starting therapy. At the start of therapy, air is circulated through the seat cushion with the Pressure Wave Technology (PWT) feature (intensity of the PWT function is set based on patient feedback). The PWT feature helps patients maintain the correct therapeutic position during therapy. Both the PWT and DHT features can be readjusted, and the PWT feature can be turned off, at any time during the session. The touch screen display guides the user step-by-step through the entire therapy procedure. During therapy, the screen displays information about the applied therapy, remaining therapy time, and main therapy parameters. Therapy is administered through clothing.

5. Indications for Use

The device is intended to provide entirely non-invasive electromagnetic stimulation of pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.

6

Image /page/6/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of a blue geometric design on the left and the text "BTL Industries" on the right. The geometric design is made up of three interlocking squares, with the letters "B", "T", and "L" inside the squares. The text "BTL Industries" is written in a gray, sans-serif font.

6. Comparison with the Predicate Device

510(k) numberK241516K181497
Device nameBTL-398HPM-6000UF
Company
nameBTL Industries, Inc.BTL Industries, Inc.
TypeSubject devicePrimary predicate
Product Code and
RegulationGastroenterology-Urology
21 CFR 876.5320
Nonimplanted Electrical Continence
Device
KPI - Stimulator, Electrical, Non-
Implantable, For IncontinenceGastroenterology-Urology
21 CFR 876.5320
Nonimplanted Electrical Continence
Device
KPI - Stimulator, Electrical, Non-
Implantable, For Incontinence
Indications for
UseThe device is intended to provide
entirely non-invasive electromagnetic
stimulation of pelvic floor musculature
for the purpose of rehabilitation of weak
pelvic muscles and restoration of
neuromuscular control for the treatment
of male and female urinary
incontinence.HPM-6000UF is intended to provide
entirely non-invasive electromagnetic
stimulation of pelvic floor musculature
for the purpose of rehabilitation of
weak pelvic muscles and restoration of
neuromuscular control for the
treatment of male and female urinary
incontinence.
Clinical UsePrescription UsePrescription Use
Intended
populationAdult Male and FemaleAdult Male and Female
Primary
FunctionPelvic floor muscle stimulationPelvic floor muscle stimulation
Principle of
ActionInitiating the action potential of nerves
results in muscle contractionInitiating the action potential of
nerves results in muscle
contraction
Type of EnergyMagnetic field (Therapy) + air (PWT
feature for proper patient positioning)Magnetic field (Therapy)
Energy Source100 - 240 V AC, 50 - 60 Hz100 - 240 V AC, 50 - 60 Hz
Number of
output
channels11
Magnetic Field
Intensity0.7 - 2.5 T0.7 - 2.5 T
Pulse Repetition
Rate1 – 150 Hz1 – 150 Hz
Pulse Width280 μς (± 20%)280 μς (± 20%)
Shape of
Stimulation PulseDual-phase, sine pulsesDual-phase, sine pulses
Therapy TimeUp to 30 minUp to 30 min
PWT featureYesNo
PWT intensity0-100%N/A
PWT repetition rateUp to 40 HzN/A
Operating
Temperature+10 to +30 °C
(50 - 86 °F)+10 to +30 °C
(50 - 86 °F)
Applicator typeChair applicatorChair applicator
Main Unit
Dimensions
(W×H×D)580 × 1380 × 580 mm
(23 × 54 × 23 in)500 × 970 × 580 mm
(20 × 38 × 23 in)
Applicator
Dimensions
(W×H×D)730 x 850 x 730 mm
(29 x 33,5 x 29 in)730 x 730 x 730 mm
(29 x 29 x 29 in)
System Weight99 kg (216 lb)82 kg (181 lb)
Applicator height
adjustment17 to 22 in (42 to 55 cm)17 to 22 in (42 to 55 cm)
Coil adjustment
(DHT Feature)Yes
100±5mm in horizontal directionNo
Therapy Modes• Basic Mode:
Frequency: 1-150 Hz, Pulse: 0.01-60 s,
Pause: 0-60s, PWT: 1-40 Hz

• Sequence Mode:
○ Amplitude modulation with PWT
1-40 Hz
○ Frequency modulation with PWT
1-40 Hz

• Single Mode:
Frequency: 1-150 Hz, Number of pulses:
1-1000 | • Basic Mode:
Frequency: 1-150 Hz, Pulse: 0.01-60 s,
Pause: 0-60s

• Sequence Mode:
○ Amplitude modulation
○ Frequency modulation

• Single Mode:
Frequency: 1-150 Hz, Number of pulses:
1-1000 |

7

Image /page/7/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of a stylized graphic of three nested squares rotated to form a diamond shape, with the letters "BTL" inside the innermost square. To the right of the graphic is the text "BTL Industries" in a simple, sans-serif font.

K241516
Page 4 of 5

8

Image /page/8/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of three blue squares nested inside each other, with the letters "BTL" in white inside the innermost square. To the right of the square logo is the text "BTL Industries" in a gray sans-serif font.

Image /page/8/Picture/2 description: The image is a rectangular shape divided into three equal sections. The rectangle is bordered by a thick black line on the top and bottom. The three sections are separated by thin black vertical lines.

As evidenced by the above table, both the subject and the predicate devices have similar intended use, but the subject and predicate devices have different technological characteristics. The differences in technological characteristics between the subject and the predicate does not raise different questions of safety or effectiveness. Performance testing was conducted to establish substantial equivalence of the subject device to the predicate device.

7. Summary of Non-clinical Testing

Below is a list of the tests that were performed and successfully completed for the subject device per the specified guidance and standards:

  • Electrical Safety testing, mechanical strength testing and thermal safety testing to ● IEC 60601-1: 2020 - Medical electrical equipment -Basic safety and essential performance.
  • Electromagnetic Compatibility testing according to IEC 60601-1-2: 2020 General ● requirements for basic safety and essential performance -- Collateral Standard: Electromagnetic disturbances -- Requirements and tests.
  • . Software Verification and Validation Testing according to FDA's Guidance (2023) . "Content of Premarket Submissions for Device Software Functions | FDA"

Additionally, performance bench data was submitted for device performance i.e., magnetic field strength testing, coil surface temperature testing/controls and PWT feature testing.

All pre-determined acceptance criteria were met.

8. Conclusion

Based on the information presented in this submission, it can be concluded that the subject device is substantially equivalent to the predicate.